Translating TCR-Based Cell Therapies into the Clinic
- Enabling technologies for allogeneic TCR-engineered Treg therapies for autoimmune disease
- Safety considerations and risk-mitigation approaches for an allogeneic TCR therapies for autoimmune disease
- Regulatory strategy and IND-enabling experience for autologous TCR-based cell therapy programs